Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
04 July, 2015 00:18 IST
Lupin can garner sales of USD 30 mn from generic Yasmin: Angel Broking
Source: IRIS Exclusive | 20 Dec, 2012, 01.20PM
Comments  |  Post Comment

Angel Broking has maintained 'Buy' on Lupin with a price target of Rs 655 in its report dated Dec. 20, 2012.

Pharma major, Lupin, announced that its subsidiary Lupin Pharmaceuticals has received final approval for its Drospirenone and Ethinyl Estradiol Tablets, 3 mg / 0.03 mg from the United States Food and Drugs Administration (FDA) to market a generic version of BayerHealthcare's (Bayer) Yasmin Tablets 3 mg / 0.03 mg.

Lupin's Drospirenone and Ethinyl Estradiol Tablets are the AB rated generic equivalent of Bayer's Yasmin Tablets 3 mg /0.03 mg. Yasmin Tablets had annual US sales of approximately USD 275 million (IMS MAT Sept 2012 sales). On a conservative side the company can garner sales of around USD 30 million and net profit of USD 9-10 million.

Click here to view full report


Disclaimer: IRIS has taken due care and caution in compilation of data for its web site. Information has been obtained by IRIS from sources which it considers reliable. However, IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website.



Lupin Limited   (Q,N,C,F)*

Comments Post comment 
By: Carol | 28 December 2012 Reply | Forward | Report Abuse 
Yasmin might have generated lots of sales, but that has more to do with heavy advertising than the quality of the pill itself. In fact, the FDA says that there might be a significantly higher chance that woman who take birth control pills with drospirenone, such as Yaz, Yasmin and Ocella, will experience a blood clot. http://www.publichealthwatchdog.com/fda-study-links-yaz-yasmin-and-other-similar-birth-control-pills-to-increased-risk-of-blood-clots/
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Shoppers Stop ties up with SAP hybris - 03-Jul-2015 16:48
Jindal Steel production climbs 38% in Apr-Jun'15 - 03-Jul-2015 16:09
SBI launches 'Project TATkal' to deliver home loan within 10 days - 03-Jul-2015 15:08
TVS Motor launches special edition 'TVS XL Super' - 03-Jul-2015 13:25
BHEL successfully achieves renovation, modernisation and uprating of 110 MW Unit - 03-Jul-2015 12:38
Persistent Systems acquires 100% stock of RGEN Solutions - 03-Jul-2015 12:05
L&T builds India's first 700mwe PHWR Nuclear Steam Generator - 03-Jul-2015 11:02
MCX inks MoU with Christ University - 03-Jul-2015 10:58
Infosys invests in Ireland following strategic partnership with AIB - 03-Jul-2015 10:55
ABB board approves to raise Rs 6 bn via NCDs - 03-Jul-2015 09:47
Spice Mobility arm acquires 26% stake in Creative Functionapps - 03-Jul-2015 09:12
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer